RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide ...Middle East

STOCKHOLM, Sweden, May 10, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock". This means that all data from the trial is now finally...

Hence then, the article about rhovac ab announces database lock in its clinical phase iib trial of onilcamotide was published today ( Wednesday 11/05/2022 - 12:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide )

Also on site :

• Today's Famous Celebrity Birthdays for March 22, 2026: Reese Witherspoon, William Shatner
• Firefighters rush to Morrisons convenience store in Oswestry after report of fire
• Iranian Revolutionary Guard: 200 Killed and Wounded Among Zionist Enemy in 73rd Wave